AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04189029 — intervention group
Intervention type: OTHER
Intervention: Extensive phenotyping
Description: Prospective assessment of physical evaluation, biomarkers and omics, cardiac and vascular imaging and telemonitoring of cardiovascular parameters for 14 days.
Study NCT03931798 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Visual Scanning Test
Description: The Visual Scanning Test (VST) involved a visual search for a target between similar visual distractors, projected in the far space, so as to simulate the search within a visual field. It is overall composed by four trials, each trial contained 20 cases and made up by 20 stimuli. On about the 80% of cases, the test provided the presence of target in the left, center or in right hemispace. In the remaining 20% of cases, the test provided the presence of a catch trial (absence of the target), to assess the presence of frontal disturbances or malingering. The test is constructed according to an increasing attentional load for the target on the left-hemispace. Participants, sitting in front a blank wall, were required to actively and free explore the projected visual field to search for the visual target, naming its identification (saying YES or NO). During the task, the examiner annotated the reaction times and the errors.
Study NCT02237937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amitriptylinoxide
Study NCT03392623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retinoic acid
Description: topical administration in melasma lesions
Study NCT03392623 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: colorimetry measurement
Description: Measurement of erythema and luminosity through a colorimeter
Study NCT02237937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Study NCT02237937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimipramine
Study NCT01270906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHIR-258 (TKI258)
Study NCT01329107 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodal Intervention
Description: Patients in the intervention group will be taught to manage their new urinary diversion BEFORE operation. Traing kit will be provided so they can train the procedure forehanded. Second they will get a personally physical training program to optimize the total body function before operation. Nutritional status will be meassured and appropriate advices will be given BEFORE operation.~After operation the intervention group will be mobilised in a fast speed compared to standard care.
Study NCT01366456 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Moxibustion
Description: Comparison of different kinds of moxibustion
Study NCT03392623 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: colorimetry measurement
Description: Measurement of erythema and luminosity through a colorimeter
Study NCT01529866 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New Abutment Connection implant
Description: New abutment connection implant
Study NCT01529866 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nanotite Certain Tapered implant
Description: Nanotite certain tapered (standard abutment connection) implant
Study NCT04434365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berberine
Description: Berberine 100 mg twice daily for 4±1 weeks (Stage 1); then, 200 mg twice daily for 4±1 weeks (Stage 2); then, 300 mg twice daily for 4 weeks (Stage 3).
Study NCT04434365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin 100 mg once daily for 12±1 weeks.
Study NCT04434365 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin 100 mg once daily for 12±1 weeks.
Study NCT04434365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel 75 mg once daily for 12±1 weeks.
Study NCT04434365 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel 75 mg once daily for 12±1 weeks.
Study NCT04434365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statin
Description: Statins once daily for 12±1 weeks.
Study NCT04434365 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Statin
Description: Statins once daily for 12±1 weeks.
Study NCT01456104 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Langerhans-type dendritic cells (a.k.a. Langerhans cells or LCs)
Description: Patients will receive a total of 5 vaccinations, comprising a primary immunization followed by four boosters at 3 week intervals with a window of ± 4 days. Vaccines will be dosed at 10x106 LCs per vaccine x 5.
Study NCT04136925 — intervention group
Intervention type: OTHER
Intervention: questionnaire
Description: questionnaire before and after race
Study NCT01994629 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM
Description: MenACWY-CRM
Study NCT01994629 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MenACWY-TT
Description: MenACWY-TT
Study NCT03169465 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: open approach
Description: open excision of the bursa and deformity then debridement of Achilles tendon
Study NCT03566901 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: G-EO System
Description: The G-EO Systems can reproduce the gait pattern and realistically simulates the ability to carry out stairs up and stairs down. It provides real-time feedback on the patient's movements with the Visual Scenario and offers the possibility to experience augmented reality further enhance the effectiveness of each therapy session. An intelligent control (G-EO System Evolution) reacts and adapts to each patient's individual capability by either supporting the patient - active assistive mode - or increasing resistance - active mode. The G-EO Systems rehabilitation robot allows to secure the subjects with a harness while they stood on the foot plates of the machine. The foot plates has 3 DoF each, allowing to control the length and the height of the steps and the foot plate angles. The maximum step length corresponded to 550 mm, the maximum achievable height of the steps is 400 mm, the maximum angles is ±90°. The maximum speed of the foot plates is 2,3 km/h.
Study NCT03566901 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physiotherapy
Description: Overground walking training including real stair climbing up/down and lower limb mobilization and stretching exercises.
Study NCT01141257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiocal® (PRS-050-PEG40)
Description: Single dose of Angiocal® i.v. (intravenous) on Day 1 and further applications of Angiocal® i.v. during a repeated dosing period.
Study NCT03169465 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic approach
Description: excision of the bursa and deformity then debridement of Achilles tendon through endoscopy
Study NCT02014363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETS6103 (low dose)
Study NCT02014363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETS6103 (high dose)
Study NCT02014363 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amitriptyline
Study NCT02864849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Study NCT02102776 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pterygium excision
Description: Pterygium head, minimal conjunctiva and anterior tenon's capsule underneath will be removed in the excision of pterygium tissue.
Study NCT03392623 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: colorimetry measurement
Description: Measurement of erythema and luminosity through a colorimeter
Study NCT03392623 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sunscreen
Description: topical administration in melasma lesions
Study NCT03392623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niacinamide
Description: topical administration in melasma lesions
Study NCT01081743 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention of the social worker
Description: Systematic home visits and regular follow-ups by phone from a social worker
Study NCT02272218 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: bariatric lap band surgery
Description: The intervention in this study is laparoscopic gastric banding (LAGB) surgery as a treatment option for obese patients with pain from knee osteoarthritis (KOA) refractory to medical treatment
Study NCT00002961 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: Arms A and B Day 2 and 3: Cyclophosphamide 60 mg/kg intravenously; Administer 20 mg/ml concentration over 2 hours.
Study NCT02864849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Study NCT02864849 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity modulated radiotherapy
Study NCT02864849 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total mesorectal excision
Study NCT01636726 — intervention group
Intervention type: DRUG
Intervention: Inhaled LABA use
Description: LABA prescription during the study period between Jan 1, 2002 and Dec 31, 2009
Study NCT00488267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ThermoProfen™ (Matrix Transdermal Ketoprofen/CHADD™ System)
Description: Transdermal patch applied to the knee for 12 hours daily.
Study NCT00002961 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporine
Description: graft vs. host disease (GVHD)prophylaxis: starting on day-1, cyclosporin 1.5 mg/kg IV every 12 hours or by continuous infusion.~When the patient tolerates adequate oral intake, cyclosporin therapy may be changed from IV to oral administration. Cyclosporin therapy should be continued at full dose until day +50. if the patient has less than Grade 2 GVHD, cyclosporin may be tapered by 5-10% weekly until completely off cyclosporin therapy.
Study NCT00488267 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Matrix/CHADD Patch
Description: Transdermal patch applied to the knee for 12 hours daily.
Study NCT00488267 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketoprofen matrix/placebo CHADD Patch
Description: Transdermal knee applied to the knee for 12 hours daily.
Study NCT01966679 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD7325
Study NCT01966679 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01794689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: 0.08mg/kg will be administered to participants randomly assigned to receive the drug via IV bolus during each quantitative sensory testing session (after one night of uninterrupted sleep and after 2 nights of forced awakenings).
Study NCT01794689 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Placebo
Description: Saline Placebo will administered to participants randomly assigned to receive the placebo via IV bolus during each quantitative sensory testing session (after one night of uninterrupted sleep and after 2 nights of forced awakenings).
Study NCT01794689 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Forced Awakenings
Description: Participants will be awakened each hour during an 8 hour sleep opportunity period. One of the awakenings is for 60 minutes and randomly determined. The other 7 awakenings are for 20 minutes each, and are randomly scheduled to occur in either the first second or third tertile of each hour. The maximum total sleep time a participant will receive is 280 minutes.
Study NCT01794689 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Forced Awakenings
Description: Participants will be awakened each hour during an 8 hour sleep opportunity period. One of the awakenings is for 60 minutes and randomly determined. The other 7 awakenings are for 20 minutes each, and are randomly scheduled to occur in either the first second or third tertile of each hour. The maximum total sleep time a participant will receive is 280 minutes.
Study NCT01794689 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Uninterrupted Sleep
Description: Participants will receive an 8 hour period of undisturbed sleep
Study NCT01794689 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Uninterrupted Sleep
Description: Participants will receive an 8 hour period of undisturbed sleep
Study NCT02481011 — intervention group
Intervention type: DRUG
Intervention: antithrombotic drugs
Study NCT04842942 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TOETVA
Description: Transoral Endoscopic Thyroidectomy Vestibular Approach
Study NCT01466972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Oral, 800mg tablet daily per cycle
Study NCT03245372 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Heart rate 60-100 beats per minute, mean arterial pressure 65 mm Hg, serum lactate 2 mmol/L, oxygen saturation 95 % (90 % during one lung ventilation).
Study NCT03245372 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Goal directed therapy
Description: The hemodynamic algorithm will be based on systolic volume index and fluid challenges. FloTrac sensor (this sensor connects to any existing arterial catheter and provides advanced hemodynamic parameters through pulse contour analysis) and EV1000 clinical platform (clinical platform from Edwards Lifesciences that provides advanced hemodynamic monitoring) will be used to calculate cardiac index and systolic volume index.
Study NCT03338699 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ShangRing
Description: Topical anesthesia based, no-flip ShangRing circumcision.
Study NCT03338699 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mogen clamp
Description: Mogen clamp circumcision
Study NCT03102164 — intervention group
Intervention type: PROCEDURE
Intervention: cardiac rehabilitation
Description: The rehabilitation protocol comprises respiratory, assisted, active dynamic, and relaxation exercises, as well as short-term isometric exercises and general strength exercises of very low intensity, short duration and properly adjusted recovery phase; they are conducted in a lying, sitting, or standing position.
Study NCT01230827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 148 (Golimumab)
Description: Patients will receive subcutaneous (SC) (under the skin) injection of golimumab 30 mg per square meter every 4 weeks from Week 0 through Week 248.
Study NCT01230827 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients who have a clinical response to golimumab at Week 16 and are randomly allocated to placebo, will receive SC injection of placebo every 4 weeks from Week 16 through Week 48.
Study NCT01230827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: All patients will receive their fixed dose of commercial methotrexate (10 to 30 mg per square meter) weekly throughout the study duration.
Study NCT01230827 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: All patients will receive their fixed dose of commercial methotrexate (10 to 30 mg per square meter) weekly throughout the study duration.
Study NCT01116726 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Description: MI sessions will involve home visits concentrating on the mitigation of behavioral risk factors for early childhood caries. These will take place shortly after childbirth and at months 6, 12, and 18.
Study NCT01116726 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced community services
Description: Enhanced community services will involve the development of culturally appropriate messages related to the mitigation of behavioral risk factors for early childhood caries through public service announcements and brochures.
Study NCT01116726 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced community services
Description: Enhanced community services will involve the development of culturally appropriate messages related to the mitigation of behavioral risk factors for early childhood caries through public service announcements and brochures.
Study NCT00889031 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: Patients with Chronic Lymphocytic Leukemia (CLL)
Study NCT02545504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Andecaliximab
Description: 800 mg administered intravenously on Days 1 and 15 of each 28-day treatment cycle
Study NCT02545504 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered intravenously on Days 1 and 15 of each treatment cycle
Study NCT02545504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Administered intravenously per standard of care on Days 1 and 15 of each treatment cycle
Study NCT02545504 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Leucovorin
Description: Administered intravenously per standard of care on Days 1 and 15 of each treatment cycle
Study NCT02545504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: Administered intravenously per standard of care on Days 1 and 15 of each treatment cycle
Study NCT02545504 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5-fluorouracil
Description: Administered intravenously per standard of care on Days 1 and 15 of each treatment cycle
Study NCT02545504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Administered intravenously per standard of care on Days 1 and 15 of each treatment cycle
Study NCT02545504 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxaliplatin
Description: Administered intravenously per standard of care on Days 1 and 15 of each treatment cycle
Study NCT02781246 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: perineural dexmedetomidine
Description: Children scheduled for arm and forearm surgery underwent supraclavicle brachial plexus blocks with ropivacaine and dexmedetomidine guided by ultrasound visualisation were randomly assigned five groups: Group A (perineural ropivacaine), Group B (ropivacaine plus 0.5 mcg/kg dexmedetomidine), Group C (ropivacaine plus 1 mcg/kg dexmedetomidine), Group D (ropivacaine plus 1.5mcg/kg dexmedetomidine) and Group E (ropivacaine plus 2 mcg/kg dexmedetomidine). In each group, children received a certain concentration of ropivacaine which adjusted by the Dixon up-and-down method for supraclavicle brachial plexus. The first child received 0.2% ropivacaine , and the concentration of ropivacaine varied by 0.1% according to the up-and-down method. The primary endpoint was the minimum local anesthetic concentration (MLAC).
Study NCT00002961 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoposide
Description: Day 4 (arms A/B): 40 mg/kg over four hours intravenously
Study NCT00002961 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: methotrexate 15 mg/m2 IV on day +1 (do not give until 24 hours after marrow infusion), and 10mg/mg2 IV on days +3 and +6.~Methotrexate may be held after two doses for bilirubin .2 mg/dL. If serum creatinine is >2x baseline, methotrexate will be omitted. If the presence of ascites or pleural effusion, methotrexate will be omitted.
Study NCT00002961 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: allogeneic bone marrow transplantation
Description: Bone marrow infusion given on day 0
Study NCT00002961 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Total Body Irradiation
Description: Day 0: Marrow Transfusion; Day 1: rest; Day 2 and 3: Cyclophosphamide 60 mg/kg; Day 4: Etopophos 40 mg/kg over four hours; Day 5,6 and 7: Total Body Irradiation (TBI) \[200 cGy twice a day (BID)\].
Study NCT00002961 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Busulfan
Description: Conditioning Regimen Arm B:~Day 0: Marrow infusion; Day 1: Rest; Day 2 and 3: Cyclophosphamide 60 mg/kg; Day 4: Etopophos 40 mg/kg over four hours; Day 5,6,7 and 8: Busulfan 0.8 mg/kg intravenous (IV) every 6 hours x 4 doses.~Patients \</= 20kg to receive busulfan 1.0 mg/kg/dose IV\*\*Busulfan oral preparation may be substituted: 1mg/kg/dose by mouth (po) for patients >20kg and 1.25 mg/kg/dose by mouth (po) for patients \</= 20 kg.
Study NCT00002961 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesna
Description: Dosing per institutional preference for hemorrhagic cystitis. Mesna 300 mg/m2 as a 15 minute infusion prior to each dose of cyclophosphamide, then at 3,6,9,12, 18 and 21 hours after initiation of each cyclophosphamide infusion. Alternative method of Mesna administration is 10 mg/kg prior to cyclophosphamide and 100 mg/kg/24 hours by continuous infusion.